Fuad El-Hibri Organization Blog » Health http://fuad-elhibri.org Fuad El-Hibri Online Mon, 30 Aug 2010 06:38:49 +0000 http://wordpress.org/?v=2.8.2 en hourly 1 Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares http://fuad-elhibri.org/2009/08/13/emergent-biosolutions-inc-ebs-ceo-chairman-10-owner-fuad-el-hibri-sells-15000-shares/ http://fuad-elhibri.org/2009/08/13/emergent-biosolutions-inc-ebs-ceo-chairman-10-owner-fuad-el-hibri-sells-15000-shares/#comments Thu, 13 Aug 2009 17:26:06 +0000 admin http://fuad-elhibri.org/?p=98
  • Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader ROCKVILLE, Md., Mar 11, 2010 (BUSINESS WIRE) — Emergent BioSolutions...
  • Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young Marie-José Daoud Awarded the Ernst and Young prize for...
  • Emergent Revises Upward 2010 Financial Forecast Company anticipates total revenues of $275 to $300 million and...
    • Related posts brought to you by Yet Another Related Posts Plugin.]]>     CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.

    EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product BioThrax? (Anthrax Vaccine Adsorbed) is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent BioSolutions Inc. has a market cap of $511.8 million; its shares were traded at around $16.91 with a P/E ratio of 13.1 and P/S ratio of 2.8.

    Reblog this post [with Zemanta]

    Related posts:

    1. Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader ROCKVILLE, Md., Mar 11, 2010 (BUSINESS WIRE) — Emergent BioSolutions...
    2. Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young Marie-José Daoud Awarded the Ernst and Young prize for...
    3. Emergent Revises Upward 2010 Financial Forecast Company anticipates total revenues of $275 to $300 million and...

    Related posts brought to you by Yet Another Related Posts Plugin.

    ]]>     http://fuad-elhibri.org/2009/08/13/emergent-biosolutions-inc-ebs-ceo-chairman-10-owner-fuad-el-hibri-sells-15000-shares/feed/ 0     Emergent BioSolutions buys flu vaccine maker http://fuad-elhibri.org/2009/07/14/emergent-biosolutions-buys-flu-vaccine-maker/ http://fuad-elhibri.org/2009/07/14/emergent-biosolutions-buys-flu-vaccine-maker/#comments Tue, 14 Jul 2009 14:51:32 +0000 admin http://fuad-elhibri.org/?p=20 Yet Another Related Posts Plugin.]]> Emergent BioSolutions has inked a deal to acquire the Protein Sciences Corporation assets for up to $75 million. The move is part of Emergent’s strategy to expand its product portfolio with a drug candidate focused on infectious disease. Currently, most of Emergent’s business comes from government contracts for biodefense. Emergent will acquire PSC’s ongoing operations, including FluBlok, a Phase III recombinant influenza vaccine candidate, and certain other assets. “The acquisition of FluBlok is consistent with Emergent’s strategy of expanding its product portfolio with a vaccine candidate focused on a major infectious disease,” said Fuad El-Hibri, Emergent’s CEO. The company recently bought rival VaxGen’s anthrax vaccine business.

    Reblog this post [with Zemanta]

    No related posts.

    Related posts brought to you by Yet Another Related Posts Plugin.

    ]]>     http://fuad-elhibri.org/2009/07/14/emergent-biosolutions-buys-flu-vaccine-maker/feed/ 0